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Azlocillin can be the potential drug 
candidate against drug-tolerant 
Borrelia burgdorferi sensu stricto 
JLB31
Venkata Raveendra pothineni1, Hari-Hara S. K. potula1, Aditya Ambati2, 
Venkata Vamsee Aditya Mallajosyula3, Brindha Sridharan6, Mohammed inayathullah  1, 
Mohamed Sohail Ahmed1 & Jayakumar Rajadas1,4,5*
Lyme disease is one of most common vector-borne diseases, reporting more than 300,000 cases 
annually in the United States. treating Lyme disease during its initial stages with traditional tetracycline 
antibiotics is effective. However, 10–20% of patients treated with antibiotic therapy still shows 
prolonged symptoms of fatigue, musculoskeletal pain, and perceived cognitive impairment. When 
these symptoms persists for more than 6 months to years after completing conventional antibiotics 
treatment are called post-treatment Lyme disease syndrome (ptLDS). though the exact reason for the 
prolongation of post treatment symptoms are not known, the growing evidence from recent studies 
suggests it might be due to the existence of drug-tolerant persisters. In order to identify effective drug 
molecules that kill drug-tolerant borrelia we have tested two antibiotics, azlocillin and cefotaxime that 
were identified by us earlier. The in vitro efficacy studies of azlocillin and cefotaxime on drug-tolerant 
persisters were done by semisolid plating method. the results obtained were compared with one of 
the currently prescribed antibiotic doxycycline. We found that azlocillin completely kills late log phase 
and 7–10 days old stationary phase B. burgdorferi. our results also demonstrate that azlocillin and 
cefotaxime can effectively kill in vitro doxycycline-tolerant B. burgdorferi. Moreover, the combination 
drug treatment of azlocillin and cefotaxime effectively killed doxycycline-tolerant B. burgdorferi. 
furthermore, when tested in vivo, azlocillin has shown good efficacy against B. burgdorferi in mice 
model. These seminal findings strongly suggests that azlocillin can be effective in treating B. burgdorferi 
sensu stricto JLB31 infection and furthermore in depth research is necessary to evaluate its potential use 
for Lyme disease therapy.
Lyme disease is a major vector-borne disease in the United States caused by Borrelia burgdorferi sensu lato which 
affects more than 300,000 people annually1–3. Lyme disease affects various organs such as brain, skin, heart, joints, 
and nervous systems4–6. The symptoms of Lyme disease are erythema migrans, fatigue, fever, headache, chills, 
muscle and joint pain7,8. Current antibiotic treatment for Lyme disease is effective during early stages of disease 
and cures the infection in most patients9. However, 10–20% of patients undergone antibiotic treatment still expe-
rience symptoms like pain, fatigue, arthralgia, and cognitive problems. If these symptoms prolong more than 
6 months after treatment, it is referred to as Post-treatment Lyme Disease Syndrome (PTLDS)9–12. Though the 
exact root cause for PTLDS is not known, research evidences suggests it might be presence of persister forms 
of B. burgdorferi or due to impaired immunological response10,13,14. Many research studies has shown that B. 
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burgdorferi establishes persistent infections after antibiotic treatment in various animal models12,13,15,16. A recent 
study in humans demonstrated that B. burgdorferi DNA was identified in PTDLS patient by xenodiagnosis but 
unable to culture viable spirochete17. In about 85% of Lyme arthritis patients, B. burgdorferi DNA was detected 
in synovial fluid by polymerase chain reaction (PCR) testing18. Eventhough the exact mechanism of how the 
Borrelia persists in an immunocompetent host is not known, a number of theories have been proposed based on 
scientific evidences. The probable mechanisms as evidenced by scientific literature are the persister formation19, 
evading immune system by hiding in the privileged sites20, surface lipoproteins modifications to avoid antigenic 
responses21, biofilm formation22,23 and immunomodulation24. Sapi etal showed the presence of Borrelia biofilm in 
the Borrelia infected Lymphocytomas22.
Like in other pathogens, several in vitro studies showed the evidence that B. burgdorferi also forms 
drug-tolerant persisters when treated with antibiotics19,25. These studies reveals that a small subpopulation of 
dormant B. burgdorferi persisters still survives with current Lyme therapy antibiotics19. Recently, it was also 
shown that B. burgdorferi infection caused by persistent biofilm/microcolonies could not be eradicated by cur-
rently prescribed drugs like doxycycline and ceftriaxone12. Due to increasing number of chronic lyme disease 
cases, there is a urgent need to find effective drug molecules which can target Borrelia persisters and Lyme asso-
ciated disorders.
Taking in to consideration of the limiting effects of standard antibiotics and our search to identify safe and 
effective molecules to kill the persisters of B. burgdorferi, we screened 7450 chemical compounds (80% FDA 
approved) from several different libraries, using a BacTiter-Glo™ Assay. We have identified nearly 300 hit mole-
cules and evaluated the top 50 hit molecules by in vitro efficacy stuides8,26. The molecules azlocillin and cefotax-
ime were chosen for the current study based on their safety and ability to kill Borrelia at low concentrations in 
in vitro8,27. Our aim was to repurpose the identified FDA approved drugs for the use of Lyme disease treatment. 
In the current study, we have shown that the azlocillin completely kills B. burgdorferi taken from both log and 
stationary phase cultures. We have generated doxycycline-tolerant persisters and reported the effect of azlocillin 
and cefotaxime individually and in combinations on these drug-tolerant persisters. We further validated our in 
vitro results by studying efficacy of azlocillin and cefotaxime against B. burgdorferi infection in C3H/HeN mice.
Results
eradication of B. burgdorferi persisters by Azlocillin and cefotaxime. In the present study, we first 
assessed the potency of azlocillin and cefotaxime against B. burgdorferi in dose dependent manner in both log 
and also stationary phase cultures of B. burgdorferi along with standard Lyme antibiotic (doxycycline). We used 
mitomycin C as a positive control and determined viability by colony forming unit (CFU) counts throughout 
the entire study19. Our results showed that the both tested antibiotics, cefotaxime at high concentration 40 μg/
ml and azlocillin at very low concentration 2.5 μg/ml could able to completely (100%) kill log phase culture of B. 
burgdorferi respectively (Fig. 1A). Similarly, azlocillin at 20 μg/ml concentration also eliminated stationary phase 
B. burgdorferi persisters completely. However, cefotaxime at highest concentration of 80 μg/ml could able to kill 
(80%) of the stationary phase B. burgdorferi persisters (Fig. 1B). More importantly, cefotaxime at increased con-
centrations from 20 to 80 μg/ml did not vary much in killing of a small persister fraction of surviving cells. The 
doxycycline, a bacteriostatic couldn’t able to kill both the log phase and stationary phase B. burgdorferi cultures 
at higher concentrations of 80 μg/ml. More than 1000 stationary phase cells were survived at doxycycline concen-
tration of 80 μg/ml. The mitomycin C at 1.25 µg/ml concentration killed B. burgdorferi both in log and stationary 
phase persisters as reported earlier19.
B. burgdorferi persisters induced by doxycycline are more tolerant to drugs. Doxycycline is most 
commonly used drug to treat Lyme disease among the antibiotics prescribed for Lyme disease. Many research-
ers have shown that doxycycline doesn’t kill B. burgdorferi completely and some population of drug-tolerant 
B. burgdorferi still exists19,25,28,29. The human maximum drug concentration (Cmax) range of doxycycline is 
between 2.6–5.9 μg/ml and has a half-life of 14 to 24 h19,30. At this doxycycline Cmax concentration range (2.5–
5.0 μg/ml), 1000–10000 cells/ml of log phase Borrelia and 10000–200000 cells/ml of stationary phase Borrelia 
still exists from the initial inoculam of 106 cells/ml (Fig. 2A,B). The fraction of B. burgdorferi persisters survived 
against doxycycline is significantly high. Further, to find drugs that can effectively kill doxycycline-tolerant B. 
burgdorferi, we have tested both azlocillin and cefotaxime on doxycycline-tolerant B. burgdorferi persisters. The 
doxycycline-tolerant B. burgdorferi that survived at both log phase and stationary phase were treated with 20 
and 40 μg/ml of azlocillin and also resuspended again with doxycycline for 7 days and plated on BSK-II aga-
rose medium for CFU. In log phase cultures, the doxycycline-tolerant B. burgdorferi that survived at 2.5 and 
5 μg/ml of doxycycline were reduced to <50 cells/ml by azlocillin. Azlocillin completely eliminated all the 
doxycycline-tolerant B. burgdorferi survived at 10 μg/ml of doxycycline treatment (Fig. 2A). As expected and also 
shown by other groups, B. burgdorferi in stationary phase were more tolerant to doxycycline11,19,29,31. Azlocillin 
significantly reduced stationary phase drug-tolerant peristers survived at 2.5 and 5 μg/ml of doxycycline treat-
ment to <300 cells. Stationary phase B. burgdorferi that persisted at 10 μg/ml of doxycycline were effectively killed 
to <200 by azlocillin(Fig. 2B). Azlocillin has effectively eliminated 99% of doxycycline-tolerant B. burgdorferi 
persisters both in log and stationary phase cultures.
The drug-tolerant B. burgdorferi persisters which persisted after treating with doxycycline were also tested 
with 40 and 80 μg/ml cefotaxime. Cefotaxime effectively kills the log phase doxycycline-tolerant B. burgdorferi 
to <10 cells (Fig. 3A). Furthermore, cefotaxime also killed stationary phase B. burgdorferi to <2500 cells, which 
are survived at 2.5 and 5 μg/ml doxycycline. Doxycycline-tolerant B. burgdorferi that persisted at 10 μg/ml dox-
ycycline were killed effectively to <200 cells when treated with cefotaxime. When the doxycycline-tolerant B. 
burgdorferi that persisted were resuspended again with doxycycline, no drastic reduction of B. burgdorferi was 
observed. Though it is statistically significant for B. burgdorferi treated at 2.5 μg/ml, the decrease in no of B. 
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burgdorferi cell growth is less with both azlocillin and cefotaxime treatment. At 5 and 10 μg/ml of doxycycline 
resuspension treatment no major reduction of B. burgdorferi growth was observed. At both log and stationary 
phase, significant growth reduction was also observed with azlocillin and cefotaxime treatment when compared 
to doxycycline resuspension (Figs. 2 and 3).
We also tested whether the colonies survived after doxycycline-tolerant B. burgdorferi persisters treated with 
azlocillin repeatedly had acquired any resistance towards drugs. So, we picked and regrown doxycycline-tolerant 
B. burgdorferi persisters that were treated with 10 μg/ml of azlocillin for 7 days in BSK-II medium. Then the 
regrown B. burgdorferi were tested by treating them again with 10, 20 μg/ml of azlocillin. These results observed 
were same as earlier and only less than 10 cells were survived (Fig. 4). From these results we have found that 
drug-tolerant B. burgdorferi peristers that survived, were treated with azlocillin did not acquire any antibiotic 
resistance mechanism. Our observation showed B. burgdorferi persisted might be typical stochastic persister cells 
which was shown earlier by other researchers19,25,32.
Azlocillin and Cefotaxime combination increases efficacy. It is known that some antibiotics act syn-
ergistically or more effective when used in combinations33. In our further studies we have tested combinations of 
azlocillin and cefotaxime to identify whether they can increase the efficiency of killing drug-tolerant persisters 
cells. The azlocillin and cefotaxime combinations could able to kill drug-tolerant B. burgdorferi persisters formed 
at 5 and 10 μg/ml of log phase cultures. The azlocillin (20 μg and 40 μg) and cefotaxime (80 μg) combinations 
reduced 2.5 μg/ml of doxycycline treated persisters(log phase) to less than 10 cells/ml (Fig. 5A). Furthermore, 
combination of 40 μg/ml azlocillin and 80 μg/ml cefotaxime effectively could able to kill stationary phase doxy-
cycline (2.5, 5 and 10 μg/ml) treated persister cultures. The drug-tolerant persisters survived in this combination 
were <10 cells/ml (Fig. 5B). Other drug combinations of azlocillin and cefotaxime (40 μg/ml azlocillin and 40 μg/
ml cefotaxime; 20 μg/ml azlocillin and 80 μg/ml cefotaxime) shown in Fig. 5B reduced the persisters generated by 
doxycycline (at concentrations 2.5, 5 and 10 μg/ml) to 10 to 100 cells/ml. Overall, the drug combinations of 40 μg/
ml azlocillin and 80 μg/ml cefotaxime is much more effective in killing persisters than using azlocillin alone. The 
azlocillin and cefotaxime combination significantly kills doxycycline-tolerant B. burgdorferi than doxycycline 
resuspension at both log and stationary phases.
Figure 1. Dose dependent killing of B. burgdorferi by antibiotics. (A) A log phase culture and (B) stationary 
phase culture. The exponential culture of B. burgdorferi culture was exposed to antibiotics for 5 days, and 
surviving cells were determined by CFU count. The culture was treated with cefotaxime, azlocillin, doxycycline 
and mitomycin C (n = 6). Error bars represent standard errors.
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time kill studies of B. burgdorferi by Azlocillin. We have observed that azlocillin kills 100% of normal 
B. burgdorferi cells and more than 99% of drug-tolerant B. burgdorferi persisters at 20 and 40 μg/ml azlocillin con-
centrations. To determine the rate of antimicrobial activity of azlocillin sodium with time, 106/ml B. burgdorferi 
(JLB31 strain) was exposed to concentrations of 20 and 40 μg/ml azlocillin drug. In 2 hrs the initial B. burgdorferi 
inoculum decreased more than 1-log10-unit at both the concentrations of azlocillin sodium (Fig. 6). By 24hrs B. 
burgdorferi load is decreased to 10000 cells/ml and by 48 hrs bacteria were reduced to 100 cells/ml (99.9%). By 96 
hrs, azlocillin has killed all B. burgdorferi persisters at both concentrations in stationary phase cultures. The doxy-
cycline Cmax concentration range of 5 μg/ml and 10 μg/ml (2x of Cmax) was used for effectivity comparision. In 
control, the B. burgdorferi growth increased to 108 cells/ml.
In silico analysis of azlocillin binding to pBps and clp proteases. Since the 3D structure for the 
pencillin-binding protein of Borrelia burgdorferi (PBP-3Bb) has not been resolved, its 3D structure was pre-
dicted using homology modeling. Penicillin-binding protein 1 A (PBP-1A) of Pseudomonas aeruginosa (PDB ID: 
5DF7), for which 3D structure is available (PDB ID: 4OON), was found to have 39% sequence similarity with 
PBP-3Bb34. Therefore, 4OON was used as the template to build the 3D structure of PBP-3Bb; in the modeled 
structure of PBP-3Bb, 87.1% of the amino acids were observed to be in the most favored region while 11.4% were 
in addition allowed region of the Ramachandran plot (supplementary Figure 1). In addition, the modeled struc-
ture showed RMSD value 0.235 A° with that of the template structure despite the moderate sequence similarity 
observed between these two proteins. These results indicate the reliability of the modeled structure for further 
Figure 2. Azlocillin killing doxycycline-tolerant B. burgdorferi. (A) A log phase culture and (B) stationary 
phase culture. The B. burgdorferi were treated different concentrations of doxycycline (2.5, 5 and 10 μg/ml) 
for 3 days, pelleted, washed and then treated again with doxycycline and azlocillin (20 and 40 μg/ml). After 
5 days the cultures were taken, washed, diluted, and plated on semisolid BSK-II medium for CFU counts 
(n = 3). Statistically significant difference between groups by two-way ANOVA followed by Tukey’s multiple 
comparisons test are indicated by ****p < 0.0001, ***p < 0.0003, and **p < 0.0088. Hash symbol represent 
eradication to the limit of detection. In the figure legend, Doxy persisters (doxycycline persisters), Doxy-tolerant 
Bb (doxycycline-tolerant B. burgdorferi), doxy-resuspension (B. burgdorferi treated again with doxycycline), 
Azlo 20 (20 μg/ml of azlocillin) and Azlo 40 (20 μg/ml of azlocillin).
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usage. Therefore, azlocillin was docked with this predicted structure of PBP-3Bb and found azlocillin binding 
with it strongly (−8.5 kcal/mol) (Fig. 7a). Five amino acids namely, GLN459, LYS507, ASN523, GLY567, GLN671 
were observed to make hydrogen bond interaction with that of azlocillin. Further, six more amino acids, namely 
TRP673, THR669, SER462, GLY461, THR670 and SER521 were found to interact with azlocillin by van der Waals 
interaction (Fig. 7b). When azlocillin was docked with the PBP of P. aeruginosa (4OON) which was used as the 
template to model PBP-3Bb, it was observed to bind in the same binding cavity as that of PBP-3Bb with similar 
binding affinity (−8.7 kcal/mol), since these two proteins folded similarly.
As clpP was reported to be upregulated by doxycycline-tolerant B. burgdorferi, we speculated that azlocillin 
mode of action against B. burgdorferi through inhibition of any of the Clp protease subunits, because we found 
azlocillin is active against doxycycline-induced persistors of B. burgdorferi32. Based on these reports, we have per-
formed molecular modeling and molecular docking on five different protease proteolytic subuntis, ClpP, ClpP1, 
ClpP2, ClpA and ClpX of B. burgdorferi. Azlocillin was found to bind with these five protease subunits with sim-
ilar binding affinity as that of with PBP-3Bb (ClpX: −9.9, ClpP: −9, ClpP2: −9, ClpP1: −8.9, ClpA: −8.8 (kcal/
mol). As the 3D structure for clpX of B. burgdorferi has not been resolved, its 3D structure was predicted using 
homology modeling based on clpX of E. coli (PDB ID 3HTE) (supplementary Figure 2). Five amino acids from 
clpX namely, LYS123, GLY122, THR124, LYS128 and ARG301 were found to interact with azlocillin by hydrogen 
bonding while four more amino acids namely, GLY120, ARG364, GLU109, GLN330 made with van der Waals 
interactions with azlocillin (Fig. 7c,d).
Figure 3. Effect of cefotaxime on doxycycline-tolerant B. burgdorferi. (A) A log phase culture and (B) 
stationary phase culture. The B. burgdorferi were treated different concentrations of doxycycline (2.5, 5 and 
10 μg/ml) for 3 days, pelleted, washed and then treated again with doxycycline and cefotaxime (40 and 80 μg/
ml). After 5 days the cultures were taken, washed, diluted, and plated on semisolid BSK-II medium for CFU 
counts (n = 3). Statistically significant difference between groups was evaluated by two-way ANOVA followed 
by Tukey’s multiple comparisons test are indicated by ****p < 0.0001, ***p = 0.0001, **p < 0.0067 and 
*p = 0.0163. Hash symbol represent eradication to the limit of detection. In the figure legend, Doxy persisters 
(doxycycline persisters), Doxy-tolerant Bb (doxycycline-tolerant B. burgdorferi), doxy-resuspension (B. 
burgdorferi treated again with doxycycline), Cefotaxime 40 (40 μg/ml of cefotaxime) and Cefotaxime 80 (80 μg/
ml of cefotaxime).
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In vivo testing of drugs in C3H/HeN mice. From our in vitro studies we have found that azlocillin and 
cefotaxime have killed B. burgdorferi effectively at low MIC and MBC concentration. Based on these results, the 
efficacy of compounds azlocillin and cefotaxime were tested in 5–6 week old female C3H/HeN mice in compa-
rision to one of the currently prescribed drug doxycycline. In order to identify more effective drugs, we have 
infected C3H mice with infective dose of B. burgdorferi (2 × 105) than the normal efficacy studies31,35. The higher 
concentration of B. burgdorferi dosage increases the infectivety rate. Mice were treated with the drugs azlocillin 
(50 mg/kg), doxycycline (50 mg/kg) and cefotaxime (30 mg/kg) once a day for five days post 7, 14 and 21 days of B. 
burgdorferi infection. Both azlocillin and doxycycline cleared B. burgdorferi completely in the 7 day infected mice. 
No B. burgdorferi growth was observed from the ears cultured in all the mice treated with azlocillin and doxy-
cline groups. In addition to it, B. burgdorferi specific DNA by qPCR was not observed in azlocillin and doxycline 
treated mice. In the cefotaxime treated mice, 1 of the 4 mice showed positive for ear cultures. The B. burgdorferi 
DNA was detected by qPCR in 2 of 4 mice from ear and also in urinary bladder of all the 4 mice of cefotaxime 
group (Table 1). In saline treated (control) group, all the mice showed positive for ear cultures and also for qPCR 
analysis of ear and urinary bladder. As expected, all the mice of the naïve group shown negative for ear cultures 
and for qPCR analysis of ear and urinary bladder.
Both azlocillin and doxycycline treatment has shown similar efficacy in the mice infected for 7 days. To iden-
tify a highly effective molecule that can clear B. burgdorferi infection we have extended infection time periods 
to 14 and 21 days. The B. burgdorferi infection reaches high titre between 14 and 21 days of postinfection and 
spreads to different organs of body like heart, spleen, kidney and joints etc36. For all the mice treated with drugs 
after 14 and 21 days of B. burgdorferi infection, ear and urinary bladders were collected for whole-DNA extrac-
tion and quantitative PCR (qPCR) analysis. In all the 4 mice infected for 14 days and treated with cefotaxime, 
high amount of B. burgdorferi DNA was detected in both ear and urinary bladder. After 14 days of infection and 
doxycycline treatment, the B. burgdorferi DNA was detected in 3 of 7 mice in ear tissue and 1 of 7 mice in urinary 
bladder. In one of the doxycycline treated mice B. burgdorferi DNA was present in both ear (high amount) and 
urinary bladder. However, for azlocillin treatment, only 2 of 8 mice has shown B. burgdorferi DNA in ear. No B. 
burgdorferi DNA was present in urinary bladder of all the 8 mice treated with azlocillin (Table 2). In all the mice 
treated with azlocillin after 21 days of infection, no B. burgdorferi DNA was detected in both ear and urinary 
bladder. But in the doxycycline group, 1 of 3 mice was detected positive for B. burgdorferi DNA in ear tissue and 
no DNA was found in urinary bladders (Table 3). As expeted all the mice (14 and 21 days of infection) in control 
group (untreated) showed large amount of B. burgdorferi DNA both in ear and uninary bladder. No presence of 
bacterial DNA in naïve mice. No B. burgdorferi was observed in ear cultures of azlocillin and doxycycline treated 
mice at day 14 and day 21. In the cefotaxime treated mice, 3 of the 4 mice showed positive for ear cultures of 14 
day infection. All the mice infected for 14 and 21 days in saline (control) group has B. burgdorferi growth in cul-
tures. No B. burgdorferi growth was observed in uninfected naïve group at day 14 and day 21.
Figure 4. B. burgdorferi persister formation is not heritable. The colonies that were recoverd after doxycycline-
tolerant B. burgdorferi (5 μg/ml) treated with 10 μg/ml azlocillin were used for the studies. The recovered 
persister colonies grown in BSK-II medium were treated with azlocillin (10 and 20 μg/ml) and plated on 
semisolid BSK-II medium. The colonies recovered after treating with 10 μg/ml azlocillin were cultured with 
fresh BSK-II medium for 7 days. Then the B. burgdorferi were treated again with azlocillin (10 and 20 μg/ml). 
After 5 days of treatment the cultures were taken, washed, and plated on semisolid BSK-II medium for CFU 
counts (n = 3). Statistically significant difference between groups was evaluated by two-way ANOVA followed 
by Tukey’s multiple comparisons test are indicated by ****p < 0.0001 and **p = 0.0085. Hash symbol represent 
eradication to the limit of detection.
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Discussion
Like many bacteria B. burgdorferi also forms persisters due to external stimuli like depriving of nutrients, pH and 
antibiotics etc29. The mechanism by which B. burgdorferi form persisters is unknown sofar. Many bacteria uses 
different type of mechanisms for the formation of persisters. The E. coli and S. Typhimurium bacteria uses identi-
fied redundant toxin-antitoxin (TA) modules for the persister formation29,37. Toxins helps in persister formation 
by decreasing the energy level of cells or by inhibiting protein synthesis29,38,39. The B. burgdorferi persisters gener-
ated by antibiotics are biphasic, with a small subpopulation of surviving cells which are not genetically modified19. 
To identify drugs that can completely eliminate B. burgdorferi we have tested drugs azlocillin and cefotaxime on 
log and stationary phase cultures. The main criteria for selection of these drugs are based on their safety and good 
efficacy with low MIC and MBC values. The cefotaxime has killed log phase culture at 40 μg/ml and unable to kill 
all the stationary phase B. burgdorferi persisters even at 80 μg/ml. The azlocillin has eradicated B. burgdorferi log 
phase culture at 2.5 μg/ml and stationary phase culture at 20 μg/ml. So far, azlocillin is the FDA approved drug 
shown that killed both B. burgdorferi log phase and stationary phase cultures completely. Azlocillin is an acylated 
form of ampicillin which is similar to the antibiotics mezlocillin and piperacillin. It is a broad range β-lactam anti-
biotic kills many pathogens which also show high activity against Pseudomonas aeruginosa40,41. It is well known 
Figure 5. Effect of Azlocillin and Cefotaxime combination on doxycycline-tolerant B. burgdorferi. (A) A log 
phase culture and (B) stationary phase culture. The B. burgdorferi were treated different concentrations of 
doxycycline (2.5, 5 and 10 μg/ml) for 3 days, pelleted, washed and then treated again with doxycycline, azlocillin 
and cefotaxime combinations. After 5 days the cultures were taken, washed, diluted, and plated on semisolid 
BSK-II medium for CFU counts (n = 3). Statistically significant difference between groups was evaluated by 
two-way ANOVA followed by Tukey’s multiple comparisons test are indicated by ****p < 0.0001 ***p = 0.001 
and **p < 0.0038. Hash symbol represent eradication to the limit of detection. In the figure legend, Doxy 
persisters (doxycycline persisters), Doxy-tolerant Bb (doxycycline-tolerant B. burgdorferi), doxy-resuspension 
(B. burgdorferi treated again with doxycycline), 40 Azlo + 80 Cefo (40 μg/ml of azlocillin + 80 μg/ml of 
cefotaxime), 40 Azlo + 40 Cefo (40 μg/ml of azlocillin + 40 μg/ml of cefotaxime) and 20 Azlo + 80 Cefo (20 μg/
ml of azlocillin + 80 μg/ml of cefotaxime).
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that cell wall-acting drugs do not kill nongrowing bacteria. One of the reason azlocillin killing B. burgdorferi 
persisters is that the stationary phase culture represents a steady state of growing and dying cells. It is shown 
recently that the stationary phase B. burgdorferi synthesize peptidoglycan at the poles and also in the middle of 
the cell19,31. Due to the production of peptidoglycan in stationary phase B. burgdorferi, other cell wall acting drugs 
like ceftriaxone and vancomycin were killing stationary phase B. burgdorferi very efficiently31. As azlocillin targets 
cell wall synthesis, this might be one of the reason that it is killing drug-tolerant persisters. It is also shown that 
β-lactams killing nonreplicative M. tuberculosis bacteria effectively when used in combination with meropenem42.
The serum levels of azlocillin and cefotaxime in the blood are higher than the MBC values to kill the B. burg-
dorferi. The Cmax concentration of cefotaxime is 125 µg/ml and azlocillin is 236.55 + /−12.9 µg/ml, which is 10 
times more than the MBC value43,44. The Cmax concentration of doxycycline is at the range of 2.6–5.9 μg/ml and 
Figure 6. Time-dependent killing of B. burgdorferi by Azlocillin. The stationary phase B. burgdorferi were 
treated with azlocillin with concentrations of 20, and 40 μg/ml and doxycycline 5 and 10 μg/ml. At all indicated 
time points an aliquot was taken, washed, diluted, and plated on semisolid BSK-II medium for CFU counts 
(n = 3). The control has no drugs. Error bars represent standard errors.
Figure 7. Molecular interactions of azlocillin with PBP-Bb (a and b) and with clpX of B. burgdorferi (c and d). 
Figures a and c displays the protein in ribbon (gray in color) and azlocillin in stick form (red in color); figures b 
and d shows the 2D view of molecular interactions in which azlocillin is shown in line form (red in color) and 
hydrogen bonds in dashed lines and respective amino acids in spheres (green in color); those amino acids which 
make van der Waals interactions are displayed spheres (light green in color).
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has a half-life of 14 to 24 h30. It is shown that at this Cmax concentration of doxycycline all the B. burgdorferi can-
not be cleared, still some subpopulation persists and exists13,19,25,28,29. Researchers has shown when the stationary 
phase B. burgdorferi were treated with Cmax concentration (2.6–5.9 μg/ml) of doxycycline nearly 104–106 cells 
still survived19,29. At this Cmax concentration of doxycycline, we also found 103–104 of log phase Borrelia and 104–
105 cells/ml of stationary phase Borrelia still exists. The fraction of B. burgdorferi subpopulation survived  with 
doxycycline treatment is significantly high. The resuspension of doxycycline-tolerant persisters again with dox-
ycycline did not show much effect as like previous studies29. This is because the Cmax concentrations of doxycy-
cline used to kill B. burgdorferi is not sufficient11,19. In our study, we have shown for the first time that azlocillin, 
an FDA approved drug is killing nearly 99.9% of doxycycline-tolerant B. burgdorferi persisters that formed at 
Cmax concentrations, both in log phase and stationary phase cultures. In comparision to azlocillin, cefotaxime 
did not eliminate doxycycline-tolerant B. burgdorferi persisters as efficiently and nearly 103 cells/ml B. burgdorferi 
persisters were survived when treated with 40 μg/ml and 80 μg/ml of cefotaxime. So, the results showed azlocillin 
effectively kills the drug-tolerant B. burgdorferi persisters. Though both antibiotics are β-lactams, azlocillin might 
use different mechanism in killing persisters. When used drug combination of azlocillin and cefotaxime, it killed 
B. burgdorferi persisters more effectively than using alone. The drug combination of 40 μg/ml azlocillin and 80 μg/
ml cefotaxime kills doxycycline persisters more effectively (less than 10 cells) compared to other combinations 
showed in the Fig. 5. Further, we also tested whether the doxycycline-tolerant persisters population that were 
treated with azlocillin have acquired resistance to drugs or persisters formed stochastically tolerating antibiotic 
stimuli. As our studies were conducted in in vitro, several factors like influence of host, immune response and 
tissue penetration etc were not taken into account. From our observation, we found persisters survived stochasti-
cally and didn’t acquire any antibiotic resistance, the same phenomenon was also observed by other researchers in 
B. burgdorferi19,29. Some researchers also observed resistant B. burgdorferi to erythromycin drugs but we did not 
observe any resistant mutants from our results shown in Fig. 445. The very peculiar feature of B. burgdorferi is that 
it doesn’t show any resistance to antibiotics. The severeal attempts made by researchers to raise mutants to amox-
illin and ceftriaxone were not successful19. The time kill studies showed that by 48 hrs 99.9% of B. burgdorferi 
were killed when treated with 20 and 40 μg/ml azlocillin. By 96 hours, all the B. burgdorferi from stationary phase 
cultures were completely killed by azlocillin. We report here for the first time that a FDA approved drugs azlocillin 
Drug name
No mice 
infected
Ear culture in 
BSK-II medium
Ear No of 
DNA copies
Urinary bladder 
No of DNA copies
Azlocillin
1 − 0 0
2 − 0 0
3 − 0 0
4 − 0 0
5 − 0 0
6 − 0 0
7 − 0 0
8 − 0 0
Cefotaxime
1 + 179 117
2 − 0 385
3 − 45 1650
4 − 0 2425
Doxycycline
1 − 0 0
2 − 0 0
3 − 0 0
4 − 0 0
5 − 0 0
6 − 0 0
7 − 0 0
Saline (control)
1 + 13088 104864
2 + 1125 30146
3 + 2212 63780
4 + 1020 30209
Naive
1 − 0 0
2 − 0 0
3 − 0 0
4 − 0 0
Table 1. In vivo efficacy of drugs against B. burgdorferi in C3H mice. After 7 days of B. burgdorferi infection, 
C3H mice were treated with following drugs once per day for 5 days (Azlocillin – 50 mg/kg, Cefotaxime – 30 mg/
kg and Doxycycline – 50 mg/kg). The whole DNA was extracted from urinary bladder and ear and analyzed by 
qPCR. The B. burgdorferi detected in the culture (+) and no B. burgdorferi detected in the culture (−).
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and cefotaxime more effectively killing both log and stationary phase B. burgdorferi cultures at clinically relevant 
concentrations in in vitro. Among these two drugs, azlocillin proved to be the most effective in eradicating the B. 
burgdorferi even at very low concentrations.
Drug name
No of mice 
infected
Ear culture in 
BSK-II medium
Ear No of DNA 
copies
Urinary bladder 
No of DNA copies
Azlocillin
1 − 0 0
2 − 0 0
3 − 0 0
4 − 0 0
5 − 104 0
6 − 90 0
7 − 0 0
8 − 0 0
Cefotaxime
1 + 3999 1264
2 + 3146 157
3 + 1585 423
4 − 218 232
Doxycycline
1 − 0 0
2 − 0 0
3 – 0 0
4 − 111 0
5 − 515 124
6 − 0 0
7 − 110 0
Saline (control)
1 + 83766 4806
2 + 3255 3177
3 + 102838 1161
4 + 372 1910
Naive
1 − 0 0
2 − 0 0
3 − 0 0
4 − 0 0
Table 2. In vivo efficacy of drugs against B. burgdorferi in C3H mice. After 14 days of Bburgdorferi infection, 
C3H mice were treated with following drugs once per day for 5 days (Azlocillin – 50 mg/kg, Cefotaxime – 30 mg/
kg and Doxycycline – 50 mg/kg). The whole DNA was extracted from urinary bladder and ear and analyzed by 
qPCR. The B. burgdorferi detected in the culture (+) and no B. burgdorferi detected in the culture (−).
Drug name
No mice 
infected
Ear culture in 
BSK-II medium
Ear No of DNA 
copies
Urinary bladder 
No of DNA copies
Azlocillin
1 − 0 0
2 − 0 0
3 − 0 0
4 − 0 0
Doxycycline
1 − 0 0
2 − 101 0
3 − 0 0
Saline (control)
1 + 3293 6194
2 + 31056 9379
3 + 11846 5472
Naive
1 − 0 0
2 − 0 0
3 − 0 0
4 − 0 0
Table 3. In vivo efficacy of drugs against B. burgdorferi in C3H mice. After 21 days of B. burgdorferi infection, 
C3H mice were treated with following drugs once per day for 5 days (Azlocillin – 50 mg/kg and Doxycycline 
– 50 mg/kg). The whole DNA was extracted from urinary bladder and ear and analyzed by qPCR. The B. 
burgdorferi detected in the culture (+) and no B. burgdorferi detected in the culture (−).
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It is shown that during doxycycline-persister formation many genes are differentially expressed compared 
to normal growth cycle of B. burgdorferi. A total of 35 genes were up-regulated two-fold and 33 genes were 
down-regulated more than two-fold. The up-regulated genes consisted of different genes including transporter 
genes, bacterial envelope protein coding genes, genes encoding chemotaxis proteins and the Clp protease gene32. 
It is known that β-lactams binds to ClpP protease and inhibits degradation of misfolded proteins leading to 
cells death46. Inactivation of the ClpXP protease in Staphylococcus aureus even leads to β-Lactam resistance47. 
As azlocillin and cefotaxime are killing doxycycline-tolerant B. burgdorferi persisters, we speculate these drugs 
may bind to B. burgdorferi ClpP protease. Though there is no evidence that ClpP protease binds to azlocillin, 
we hyphothesized based on available published data32. When we docked the azlocillin with five different Clp 
subunits, azlocillin was found to bind with maximum affinity with ClpX (−9.9 kcal/mol). The ClpX in bacteria 
has been known as important for protein unfolding, degradation and regulation of protein quality and turnover 
through controlled proteolysis48,49. The stronger binding of azlocillin with B. burgdorferi ClpX suggest that ClpX 
might be a potential target for azlocillin in addition to PBP-Bb. However, this observation needs to be experimen-
tally verified in B. burgdorferi.
At the same time, the recent findings showed biosynthesis of bacterial cell wall takes place in non-growing 
B. burgdorferi stationary phase cultures by continious synthesis of peptidoglycan31. Penicillin-binding proteins 
(PBPs) play a major role in transglycosylation and transglycosylation steps for peptidoglycan synthesis50. The 
β-lactam drugs bind to PBPs and prevent either transglycosylation or transglycosylation steps which leads to dis-
ruption of bacterial of cell wall synthesis51. The crystallography structural studies shows azlocillin binds strongly 
to penicillin-binding protein 3 (PBP 3) of Pseudomonas aeruginosa34. Considering these studies, we have per-
formed in silico analysis of azlocillin interacting with pencillin-binding protein of Borrelia burgdorferi (PBP-3Bb). 
We have found that azlocillin binds strongly with PBP-3Bb with binding affinity of −8.5 kcal/mol. Based on the 
co-relation of our in silico studies with the experimental findings of azlocillin binding to PBPs in other bacteria we 
speculate that PBP-3Bb can be one of potential target for azlocillin. In addition to it, studying of azlocillin binding 
to alternative targets cannot be excluded.
In this current study, we examined the efficacy of azlocillin and cefotaxime post 7, 14 and 21 infection in 
C3H mice model. We have inoculated higher dose of B. burgdorferi (2 × 105) because they replicate fastly in high 
titres and spreads to tissue sites effectively. Cefotaxime treatment failed to eradicate the B. burgdorferi infection 
completely in mice infected for 7 and 14 days. We found both doxycycline and azlocillin cleared  Borrelia infec-
tion at 7 days of infection. In order to study the relative efficacies of doxycycline and azlocillin in mice we have 
choosen 14 and 21 days of infection. The severity of infection (carditis and arthritis) is more at 14 and 21 days of 
infection36. Doxycline did not cleared B. burgdorferi completely in all the mice post 14 and 21 days of infection. 
B. burgdorferi DNA is detected in 3 of 7 mice post 14 days infection and 1 of 3 mice post 21 days infection of dox-
ycline treatment. Though the azlocillin eliminated B. burgdorferi infection completely in all the mice infected for 
21 days still 2 of 8 mice infected for 14 days has some B. burgdorferi DNA in ear tissues. Azlocillin showed more 
efficacy than doxycycline post 14 and 21 days of infection. Many studies have also shown that even after longterm 
treatment with doxycycline and ceftriaxone still some B. burgdorferi DNA was detected in mice and rhesus maca
ques13,16,35,52,53. It is well known that in 10–20% of the people treated with Lyme disease have PTLDS. The PTLDS 
might be either due to presence of persistence bacteria or due to its residual particles left over after the infection. 
Irrespective of causing factors for PTLDS, effective treatment of Lyme patients with more potent drugs can min-
imize exposure of patients to infection which can prevent PTLDS.
As it is not convenient to use intravenous drugs like azlocillin for treatment compared to oral available drugs, 
experiments are ongoing for developing oral delivery of azlocillin. Further efficacy studies should be done by long 
term treatment with azlocillin to check whether it can clear the B. burgdorferi in all the infected mice completely. 
These results are very encouraging to conduct further in vivo studies on different B. burgdorferi strains. Though 
azlocillin showed good efficacy in C3H mice model, further studies should be done in in vivo persisters model 
to prove whether these drugs have potential to eliminate persisters or not. In addition to it, further additional 
preclinical and clinical studies should conduct for repurposing these drug molecules and clinical acceptance, 
thereafter.
Materials and Methods
Bacterial strains and culture. The low passage B. burgdorferi sensu stricto strain JLB31 was (generously 
provided by Dr. Linden Hu Tufts University, Boston, MA, USA) cultured in Barbour-Stoenner-Kelly II (BSK-II) 
complete medium supplemented with 6% rabbit serum (Sigma, St.Louis, MO, USA). The cultures were incubated 
in sterile 50 mL falcon tubes (Corning Incorporated, Corning, NY, USA) at 33 °C for 3–7 days in 5% CO2 incu-
bator without antibiotics.
Semisolid plating was chosen to obtain the exact count of the growing borrelial colonies as colony forming 
units (CFU). We performed semisolid plating procedure as described by Jenny A. Hyde etal54. The 2X BSK-II 
medium was prepared in the following manner. To the 500 ml of CMRL-1066 medium: 50 g of bovine serum albu-
min (Sigma), 5 g neopeptone (BD), 6.6 g HEPES acid (Sigma), 0.7 g sodium citrate (Sigma), 5 g glucose (Sigma), 
2 g yeastolate (BD), 2.2 g sodium bicarbonate (Fisher), 0.8 g sodium pyruvate (Sigma), 0.4 g N-acetyl-glucosamine 
(Sigma) were added and mixed thoroughly. Finally pH of the medium was adjusted to 7.6 and filtered through 
0.2 µm filter units. For plating the medium is mixed in the following way. The 100 ml of 2X BSK-II medium 
prewarmed at 55 °C was mixed with 100 ml 1.7 ml of agarose (55 °C) and 14 ml sterilized rabbit serum and equil-
ibrated to 55 °C. Then 10 ml of equilibrated BSK-II medium was dispensed into 60-mm petri dishes as bottom 
agar and allowed to solidify. Finally, the sample was resuspended in 0.5 ml fresh BSK-II medium and mixed with 
10 ml of BSK-II agarose medium (55 °C) and poured as a top agar. The plates were incubated in the incubator with 
5% CO2 at 33 °C for minimum of 21 days. The white visible colonies were counted after 21 days for the analysis.
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Antimicrobial agents. The 10 mM of drug stocks of Azlocillin sodium salt (Cayman chemicals, Ann Arbor, 
MI), Cefotaxime acid (Cayman chemicals) and Doxycycline (sigma) were prepared by dissolving in sterile dis-
tilled water. The 10 mM Mitomycin C stock was prepared by solubilizing in DMSO.
Dose-dependent killing of B. burgdorferi. The dose-dependent killing of B. burgdorferi was performed 
with log phase (3 days old) and stationary phase (7 days to 10 days old). To determine efficacy of drugs, 2 × 106/
ml of Borrelia were used from log and stationary phase cultures and grown in BSK-II medium in 48-well plates 
with drugs at varying concentrations ranging from 1.25, 2.5, 5, 10, 20, 40 and 80 μg/ml. The Borrelia cultures were 
incubated at 33 °C with 5% CO2 for 5 days. After 5 days the cultures were centrifuged at 13,000 rpm for 10 min-
utes. Then the pellets were washed, resuspended in 0.5 ml of fresh BSK-II medium and serially diluted. Finally, the 
cultures diluted in 0.5 ml BSK-II medium were mixed with 10 ml of BSK agarose and poured as top agar. Plates 
were incubated at 33 °C with 5% CO2 up to 21 days and visible colonies were counted. The experiments were done 
atleast thrice in triplicates.
Determining efficacy of drugs on doxycycline tolerant persisters. The 106/ ml of Borrelia taken 
from log and stationary phase were cultivated with varying doxycycline concentrations of 2.5, 5 and 10 μg/ml. The 
doxycycline cultivated Borrelia cultures were incubated in 48-well plates for 3 days at 33 °C with 5% CO2. Then 
the cultures were centrifuged for 10 minutes at 13,000 rpm. The remaining doxycycline tolerant Borrelia pellets 
were washed and incubated with 1 ml of BSK-II medium containing drugs of varying concentrations for 7 days. 
As a control doxycycline tolerant Borrelia obtained were also resuspended again with doxycycline concentrations 
of 2.5, 5 and 10 μg/ml. After incubation for 7 days the cultures were pelleted, washed and resuspended in 0.5 ml of 
fresh BSK-II medium. Then the semisolid plating was done by mixing cultures diluted in 0.5 ml BSK-II medium 
with 10 ml of BSK agarose and poured as top agar. The agar plates were incubated at 33 °C with 5% CO2 up to 21 
days. The white visible colonies were counted for generating persister curve. All the experiments were done atleast 
thrice with triplicates.
time-dependent killing studies. Time kill studies were performed with Borrelia isolate JLB31 (B. burg-
dorferi s.s.) to determine the rate of antimicrobial activity of azlocillin. The106 per mL Borrelia were grown in 
BSK-II medium with azlocillin at concentrations 20 and 40 μg/ml and doxycycline at concentrations 5 and 10 μg/
ml. BSK-II medium with no drugs was used as a control. At time intervals of 2, 6, 10, 24, 48, 96 and 144 hours 
B. burgdorferi cultures were centrifuged for 10 minutes at 13000 rpm and the pellet was resuspended in 0.5 ml of 
fresh BSK-II medium, serially diluted, mixed with 10 ml of BSK agarose and poured as top agar. After 21 days 
antibacterial activity was analyzed by counting bacteria colonies at all the time points performed. The experiment 
was done once with triplicates.
In vivo testing of drugs in C3H/HeN mice. Four weeks old female C3H/HeN mice, were purchased from 
Charles River Laboratories, Wilmington, Massachusetts. All mice were maintained in the pathogen-free animal 
facility according to animal safety protocol guidelines at Stanford University under the protocol ID APLAC-
30105. All experiments were in accordance with protocols approved by the Institutional Animal Care and Use 
Committee of Stanford University. The mice were infected intradermally with 0.1 mL BSK medium containing 
2 × 105 B. burgdorferi JLB31. On the 7, 14 and 21 days of infection, the mice were intraperitoneally administered 
a daily dose of drugs, azlocillin (50 mg/kg), cefotaxime (30 mg/kg) and doxycycline (50 mg/kg) for 5 consecutive 
days (Tables 1, 2 and 3). After 48 hours of the last dose of administering compounds, the mice were sacrificed 
and their urinary bladders, ears, and hearts were cultured in BSK-II medium. The cultures were evaluated for 
the presence of motile spirochetes after 21 days using the dark-field microscopy51. The DNA was extracted from 
urinary bladder and ear. If the B. burgdorferi was observed in any one of the organ in the mice, the animal was 
considered as infected. The absence of B. burgdorferi propagation marked the effectiveness of the treatment in 
these organisms.
Quantitative Real-time pcR (qpcR) analysis of B. burgdorferi DnA from tissues. Urinary blad-
der, ear punches (20 mg per sample) were homogenized and DNA was extracted using the NucleoSpin tissue 
kit according to the manufacturer’s instructions (Düren, Germany). qPCR from above tissues were performed 
in blinded samples using three oligonucleotides, two primers and a probe for B. burgdorferi Fla-B gene. These 
primers were listed as follows: Fla-B primers Flab1F 5′-GCAGCTAATGTTGCAAATCTTTTC-3′, Flab1R 
5′-GCAGGTGCTGGCTGTTGA-3′ and TAMRA Probe 5′-AAACTGCTCAGGCTGCACCGGTTC-3' accord-
ing to the published protocol. The amplification protocol consisted of 10 min at 95 °C, followed by 40 cycles of 
amplification (95 °C for 15 s and 60 °C for 1 min). A negative result was assigned where no amplification occurred 
or if the threshold cycle (CT) was greater than 36. Reactions were performed in duplicate for each sample. Results 
were plotted as the number of Borrelia per microgram of tissue. The lower limit of detection was 1 to 100 copies of 
B. burgdorferi Fla-B DNA per mg of tissue. In addition to standard laboratory measures to prevent contamination, 
negative controls (containing PCR mix, Fla-B primers, and Taq polymerase devoid of test DNA) were included.
Molecular docking. The three-dimensional structure of pbp of B. burgdorferi was not available, so it was 
built using homology modelling by employing SWISS-MODEL55. The pencillin-binding protein (PBP) of P. 
aeruginosa was identified as the homologous protein using BLASTP and hence it was used as the template for 
building the three-dimensional structure for the borrelia PBP. The quality of the modeled structure was verified 
using Ramachandran plot (Laskowski et al., 1993 and56 and superimposition of modeled structure with that of 
the template structure was carried using Chimera57. Azlocillin was docked with modeled structure of borrelia PBP 
using AutoDock Vina58. Molecular interaction between Azlocillin and borrelia PBP was analyzed using Discovery 
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Studio visualizer (version 4.0). Similarly, molecular modeling and docking studies were carried out for five of the 
protease proteolytic subunits of B. burgdorferi.
Statistical analysis. Statistical analysis was performed using GraphPad Prism 7 software. Data sets were 
analyzed by two-way ANOVA with Tukey’s multiple comparisons test for pair-wise comparisons. Significant p 
values are indicated as ****p < 0.0001 and *p < 0.05.
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